IL-6 activates the corresponding receptor IL-6R on tumour cells and CAFs by means of autocrine–paracrine, which leads to differential activation of the STAT3 and MEK/ERK signalling pathways, resulting in tumour development. The gene discussed is STAT3; the disease is neoplasm.